CO2024001102A2 - Compuestos de pirazolopiridinona - Google Patents
Compuestos de pirazolopiridinonaInfo
- Publication number
- CO2024001102A2 CO2024001102A2 CONC2024/0001102A CO2024001102A CO2024001102A2 CO 2024001102 A2 CO2024001102 A2 CO 2024001102A2 CO 2024001102 A CO2024001102 A CO 2024001102A CO 2024001102 A2 CO2024001102 A2 CO 2024001102A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- pyrazolopyridinone
- pyrazolopyridinone compounds
- cancer
- activating
- Prior art date
Links
- TUPZMLLDXCWVKH-UHFFFAOYSA-N pyrazolo[4,3-b]pyridin-3-one Chemical class C1=CN=C2C(=O)N=NC2=C1 TUPZMLLDXCWVKH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000006052 T cell proliferation Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En el presente documento se describe un compuesto de la fórmula (I) para activar las células T, promover la proliferación de las células T y/o mostrar una actividad antitumoral, un método para usar los compuestos que se dan a conocer en el presente documento para el tratamiento del cáncer y una composición farmacéutica que comprende los mismos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021110407 | 2021-08-03 | ||
| CN2022103862 | 2022-07-05 | ||
| CN2022106484 | 2022-07-19 | ||
| PCT/CN2022/109663 WO2023011456A1 (en) | 2021-08-03 | 2022-08-02 | Pyrazolopyridinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024001102A2 true CO2024001102A2 (es) | 2024-04-29 |
Family
ID=85155227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0001102A CO2024001102A2 (es) | 2021-08-03 | 2024-01-31 | Compuestos de pirazolopiridinona |
Country Status (9)
| Country | Link |
|---|---|
| KR (1) | KR20240051948A (es) |
| CN (1) | CN117836296A (es) |
| AR (1) | AR126693A1 (es) |
| AU (1) | AU2022321703A1 (es) |
| CA (1) | CA3228862A1 (es) |
| CO (1) | CO2024001102A2 (es) |
| IL (1) | IL310528A (es) |
| TW (1) | TW202315620A (es) |
| WO (1) | WO2023011456A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| CN117567466B (zh) * | 2024-01-16 | 2024-04-16 | 成都金瑞基业生物科技有限公司 | 一种喹唑啉衍生物的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641455B1 (en) * | 2003-06-27 | 2008-08-06 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| DK1641454T3 (da) * | 2003-06-27 | 2009-02-09 | Pfizer Prod Inc | Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere |
| US20220387401A1 (en) * | 2019-07-04 | 2022-12-08 | Lead Pharma Holding B.V. | Estrogen-related receptor alpha modulators |
| WO2021074365A1 (en) * | 2019-10-18 | 2021-04-22 | Lead Pharma Holding B.V. | ESTROGEN-RELATED RECEPTOR ALPHA (ERRα) MODULATORS |
-
2022
- 2022-08-02 CA CA3228862A patent/CA3228862A1/en active Pending
- 2022-08-02 WO PCT/CN2022/109663 patent/WO2023011456A1/en active Application Filing
- 2022-08-02 TW TW111129001A patent/TW202315620A/zh unknown
- 2022-08-02 IL IL310528A patent/IL310528A/en unknown
- 2022-08-02 CN CN202280053906.2A patent/CN117836296A/zh active Pending
- 2022-08-02 AU AU2022321703A patent/AU2022321703A1/en active Pending
- 2022-08-02 KR KR1020247007135A patent/KR20240051948A/ko unknown
- 2022-08-03 AR ARP220102081A patent/AR126693A1/es unknown
-
2024
- 2024-01-31 CO CONC2024/0001102A patent/CO2024001102A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR126693A1 (es) | 2023-11-01 |
| AU2022321703A1 (en) | 2024-02-15 |
| IL310528A (en) | 2024-03-01 |
| KR20240051948A (ko) | 2024-04-22 |
| CN117836296A (zh) | 2024-04-05 |
| TW202315620A (zh) | 2023-04-16 |
| CA3228862A1 (en) | 2023-02-09 |
| WO2023011456A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024001102A2 (es) | Compuestos de pirazolopiridinona | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| PE20231739A1 (es) | Compuestos triciclicos de urea como inhibidores de jak2 v617f | |
| CL2022001710A1 (es) | Derivados bicíclicos sustituidos de piperidina útiles como activadores de células t | |
| CO2024003949A2 (es) | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos | |
| CL2022001951A1 (es) | Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2023001637A1 (es) | Inhibidores de la vía jak1 para el tratamiento del vitíligo. | |
| CR20220553A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| CO2021018155A2 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| CL2023001534A1 (es) | Compuesto de heteroarilcarboxamida | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CL2023000061A1 (es) | Macrociclos y su uso | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| UY39574A (es) | Compuesto macrocíclico útil para tratar el cáncer y composición farmacéutica que lo contiene | |
| CL2023002966A1 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| CL2022002786A1 (es) | Formas cristalinas de compuestos orgánicos | |
| DOP2022000127A (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos. | |
| UY39434A (es) | Nuevos compuestos | |
| BR112023020669A2 (pt) | Terapias de combinação para o tratamento de câncer |